[Drug-eluting stents in coronary arteries]

The Swedish Council on Health Technology Assessment (SBU)
Record ID 32010001105
Authors' recomendations: Compared with bare metal mesh stents, drug-eluting stents prevent the recurrence of narrowing of the coronary artery, without increasing the risk of complications. This applies to both stable and unstable coronary artery disease. Various drug-eluting stents may differ in both effect and risks: Everolimus-eluting stents give rise to fewer stent thromboses than sirolimus-eluting stents, and fewer myocardial infarctions and stent thromboses than paclitaxel-eluting stents. However, in comparative studies, there seem to be no differences in safety or effect of everolimus-, biolimus- or second-generation zotarolimus-eluting stents.
Project Status: Completed
Year Published: 2014
URL for published report: http://www.sbu.se/201406e
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: Sweden
MeSH Terms
  • Coronary Vessels
  • Drug Delivery Systems
Organisation Name: Swedish Agency for Health Technology Assessment and Assessment of Social Services
Contact Address: P.O. Box 3657, SE-103 59 Stockholm, Sweden. Tel: +46 8 4123200, Fax: +46 8 4113260
Contact Name: info@sbu.se
Contact Email: info@sbu.se
Copyright: The Swedish Council on Health Technology Assessment (SBU)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.